Vaccine-Based Prevention of Meningococcal B Disease:Tools for Interpreting and Implementing Recommendations

Meningococcal disease, specifically serotype B (MenB), is an ongoing problem in this country. The disease can develop from initial symptoms to death within 24 hours. Given how disabling this disease can be it is essential health care workers, who deliver vaccinations, enhance their standards of care in practice in order to deliver the highest rates of preventative care in this area. The goal of the activity is to improve comprehension and initiate practice changes so as to improve immunization rates for all patients who are currently scheduled for the MenB vaccination.

Support:

This activity is supported by an independent grant from GlaxoSmithKline.

Target Audience

Primary care clinicians, pediatricians, nurses, pharmacists, physician assistants, and all clinicians who treat children/adolescents who are scheduled to receive the MenB vaccine.

Learning Objectives

At the conclusion of this activity, participants will be able to (or better able to): 

  1. Differentiate between types of meningococcal vaccinations with respect to serotypes covered, administration schedule, impact on herd protection and tolerability.
  2. Interpret Category A and B recommendations in order to better discuss meningococcal B vaccination for patients.
  3. Utilizing case-based video vignettes, implement strategies to improve uptake of meningococcal B vaccine in clinical practice.

Additional Information

AttachmentSize
PDF icon CME Future State ED.pdf213.3 KB
Course summary
Available credit: 
  • 1.00 AAFP Elective
  • 1.00 AAP
    This continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 1.00 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
03/09/2021
Course expires: 
03/09/2022

 

 

Stephen I. Pelton, MD
Course Director
Professor of Pediatrics
Boston University School of Medicine
Professor of Epidemiology
Boston University School of Public Health
Director, Section of Pediatric Infectious Diseases
Boston Medical Center

Dr. Pelton receives Grant/Research/Clinical Trial Support from Pfizer, Merck and Cempra. He is a consultant for Pfizer, GlaxoSmithKline, Sanofi Pasteur and Seqirus.

Gary Marshall, MD
Professor of Pediatrics,
Chief, Division of Pediatric Infectious Diseases
University of Louisville School of Medicine
Louisville, KY

Dr. Marshall receives grant and research support from GlaxoSmithKline, Merck, Pfizer, Sanofi Pasteur and Seqirus. He is a speaker for Sanofi Pasteur.

Carole Moloney, RN, MSN, CPNP
Clinical Instructor of Pediatrics
Boston University School of Medicine
Boston, Massachusetts

Dr. Moloney is on the speaker’s bureau for Sanofi Pasteur.

 

Disclosure link: 
Company Information

AMA
Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Boston University School of Medicine designates this enduring material for a maximum of  1.00 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC
Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Contact Hours: 1.00. Pharmacotherapy Hours: 1.00.

ACPE
The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This is a knowledge-based educational activity. Pharmacists will receive 1.00 contact hour (0.1 ceus) for the enduring educational activity. No partial credit is available. UAN: 0060-9999-21-012-H06-P

AAFP
The AAFP has reviewed "Vaccine-Based Prevention of Meningococcal B Disease: Tools for Interpreting and Implementing Recommendations" and deemed it acceptable for up to 1.00 Enduring Materials, Self-Study AAFP Elective credit. Approval is from 02/26/2021 to 02/26/2022. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAP
This continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 1.00 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.

Available Credit

  • 1.00 AAFP Elective
  • 1.00 AAP
    This continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 1.00 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.